Skip to Main Content
Contribute Try STAT+ Today

Biotech is celebrating a platinum anniversary next week: 20 years since J.P. Morgan took over the industry’s biggest conference, an annual ritual of brokered mergers, broken promises, and breakthrough science.

The J.P. Morgan Healthcare Conference is more than a venue for deals. It’s a place where fierce arguments break out, where industry memes get made, and where biotech examines its warts and wrinkles.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Plenty of American died, lost their jobs and livelihoods, due to the corrupt activities of JPM. The regulatory agencies no longer function in any meaningful way to reign in this profit driven nightmare. Paid off politicians and eviscerated regulatory agencies, have helped drive the obscene profits. Hopefully the American People are catching on to all of it, even though groups like this continue to mislead the public and undermine democracy.

Comments are closed.